KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Other Accumulated Expenses (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Other Accumulated Expenses for 12 consecutive years, with $1.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Other Accumulated Expenses rose 79.3% to $1.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $1.0 million, a 79.3% increase, with the full-year FY2023 number at $120000.0, down 75.16% from a year prior.
  • Other Accumulated Expenses was $1.0 million for Q3 2024 at Palvella Therapeutics, up from $1.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q3 2024 to a low of $120000.0 in Q4 2023.
  • A 5-year average of $498368.4 and a median of $497000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 252.6% in 2022, then tumbled 75.16% in 2023.
  • Palvella Therapeutics' Other Accumulated Expenses stood at $347000.0 in 2020, then rose by 13.26% to $393000.0 in 2021, then grew by 22.9% to $483000.0 in 2022, then crashed by 75.16% to $120000.0 in 2023, then soared by 759.17% to $1.0 million in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Other Accumulated Expenses are $1.0 million (Q3 2024), $1.0 million (Q2 2024), and $335000.0 (Q1 2024).